Rebalancing disease, restoring health.
Adrestia is developing therapeutics that work in an entirely new way– restoring the biological balance in damaged, diseased, or dying cells. Its platform is focused on applying the latest technical advances to identify therapeutics for rare diseases that apply a concept known as synthetic viability. It is the latest venture of our Science Partner, Professor Steve Jackson (who invented Olaparib/Lynparza, the breast and ovarian cancer drug partnered between AstraZeneca and Merck, valued as an asset at $17BN).
Professor Steve Jackson
Genetics & Platform Technologies